ERBB2 and cancer: In conclusion, the retrospective study including 98 breast cancer patients treated with anti-Her-2 therapy revealed that tumor TILs as well as its FOXP3+, CD68+ phenotypes in stromal site, and expression of FOXP3 in cancer cells were significantly associated with OS.